2022
Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033): A Phase II Randomized Trial of Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab in Women With Stage I HER2-Positive Breast Cancer
Bellon JR, Tayob N, Yang DD, Tralins J, Dang CT, Isakoff SJ, DeMeo M, Burstein HJ, Partridge AH, Winer EP, Krop IE, Tolaney SM. Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033): A Phase II Randomized Trial of Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab in Women With Stage I HER2-Positive Breast Cancer. International Journal Of Radiation Oncology • Biology • Physics 2022, 113: 117-124. PMID: 34990776, DOI: 10.1016/j.ijrobp.2021.12.173.Peer-Reviewed Original ResearchConceptsHER2-positive breast cancerBreast-conserving surgeryStage I HER2-positive breast cancerT-DM1 armBreast radiation therapyT-DM1Radiation therapySkin toxicityBreast cancerBCS patientsWBRT patientsInvasive disease-free survival eventsDisease-free survival eventsInvasive disease-free survivalHuman epidermal growth factor receptor 2Phase II Randomized TrialWhole breast radiation therapyEpidermal growth factor receptor 2Adjuvant T-DM1Adjuvant trastuzumab emtansineEfficacy of HER2RT-related toxicityWeeks of therapyAcute skin toxicityAnti-HER2 therapy
2021
Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033), a Phase II Randomized Trial of Adjuvant T-DM1 vs. TH in Women With Stage I HER2 Positive Breast Cancer
Bellon J, Tayob N, Burstein H, Partridge A, Demeo M, Tralins J, Yang D, Dang C, Isakoff S, Yardley D, Valero V, Winer E, Krop I, Tolaney S. Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033), a Phase II Randomized Trial of Adjuvant T-DM1 vs. TH in Women With Stage I HER2 Positive Breast Cancer. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: s34. DOI: 10.1016/j.ijrobp.2021.07.103.Peer-Reviewed Original ResearchT-DM1 armBreast conserving surgeryPartial breast irradiationT-DM1Radiation therapyBreast cancerLocal recurrenceSkin toxicityGrade 2 acute skin toxicityProspective randomized phase II studyGrade 3 skin toxicityHormone receptor-positive diseaseRandomized phase II studyPhase II Randomized TrialAdjuvant T-DM1Conclusions Radiation therapyGrade 2 pneumonitisGrade 3 pneumonitisIpsilateral rib fracturesPhase II studyReceptor-positive diseaseWeeks of therapyAcute skin toxicityAnti-HER2 therapyNodal radiation therapy
2018
Multikinase inhibitor sorafenib induces skin toxicities in tumor-bearing mice
Tian A, Lu H, Zhang J, Fu S, Jiang Z, Lam W, Guan F, Chen L, Feng L, Cheng Y. Multikinase inhibitor sorafenib induces skin toxicities in tumor-bearing mice. Cancer Chemotherapy And Pharmacology 2018, 81: 1025-1033. PMID: 29633006, DOI: 10.1007/s00280-018-3575-y.Peer-Reviewed Original ResearchConceptsSkin lesionsConcentrations of sorafenibBDF1 miceNude miceTGF-β1/SmadSevere cutaneous lesionsInduced skin lesionsTumor growth factorTumor-bearing miceSkin of miceSmooth muscle actinCell nuclear antigenF4-80Ly6GSkin rashConclusionsThe severityCutaneous lesionsSkin toxicitySorafenib treatmentPathological scoresSkin reactionsMultikinase inhibitorPathologic changesAnimal modelsHigh doses
2015
Anal cancer outcomes in patients treated with intensity modulated versus 3-dimensional chemoradiotherapy.
Cooper B, Grew D, Bitterman D, Sanfilippo N, Du K. Anal cancer outcomes in patients treated with intensity modulated versus 3-dimensional chemoradiotherapy. Journal Of Clinical Oncology 2015, 33: 662-662. DOI: 10.1200/jco.2015.33.3_suppl.662.Peer-Reviewed Original ResearchDistant metastasis-free survivalLocal recurrence-free survivalColostomy-free survivalOverall survivalTreatment interruptionLymph nodesTreatment breaksSkin toxicityRadiation therapyThree-year overall survivalAnal cancer outcomesGrowth factor supportRecurrence-free survivalMetastasis-free survivalSquamous cell carcinomaKaplan-Meier survivalConformal radiation therapyRadiation techniquesLog-rank statisticsChi-square testAcute gastrointestinalAcute GIDefinitive chemoradiotherapyIMRT cohortRTOG 0529
2014
Enhanced skin toxicity associated with the combination of clofarabine plus cytarabine for the treatment of acute leukemia
Zhang B, Bolognia J, Marks P, Podoltsev N. Enhanced skin toxicity associated with the combination of clofarabine plus cytarabine for the treatment of acute leukemia. Cancer Chemotherapy And Pharmacology 2014, 74: 303-307. PMID: 24908437, DOI: 10.1007/s00280-014-2504-y.Peer-Reviewed Original ResearchConceptsAcute leukemiaSkin toxicityCombination of clofarabineInitiation of chemotherapyPalmar-plantar erythrodysesthesiaCutaneous side effectsTwo-drug combinationsDifferent chemotherapeutic agentsCytarabine chemotherapyCytarabine groupResultsTen patientsCutaneous toxicityToxic erythemaCutaneous reactionsSkin findingsMedical recordsInstitutional experienceSevere formSide effectsPatientsBody foldsClofarabineChemotherapeutic agentsChemotherapyLeukemiaA phase II trial of balloon-catheter partial breast brachytherapy optimization in the treatment of stage 0, I, and IIA breast carcinoma
Nath SK, Chen ZJ, Rowe BP, Blitzblau RC, Aneja S, Grube BJ, Horowitz NR, Weidhaas JB. A phase II trial of balloon-catheter partial breast brachytherapy optimization in the treatment of stage 0, I, and IIA breast carcinoma. Journal Of Radiation Oncology 2014, 3: 371-378. PMID: 25485042, PMCID: PMC4254816, DOI: 10.1007/s13566-014-0153-8.Peer-Reviewed Original ResearchSuperior PTV coverageSkin toxicityPTV coverageStage 0Single-arm phase II studyAcute grade 2 toxicityGrade 2 skin toxicityCommon acute toxicitiesGrade 1 erythemaGrade 1 fibrosisGrade 2 toxicityPhase II studyPhase II trialPartial breast irradiationBalloon catheter brachytherapyLower skin dosesOverall low rateMedian V90II trialPrimary endpointII studyAdditional patientsTreatment eligibilityBreast irradiationBrachytherapy results
2013
A Pilot Study Of Sorafenib In Refractory Or Relapsed T-Cell Lymphoma Patients
Fraser J, Lansigan F, Seropian S, Barbarotta L, Foss F. A Pilot Study Of Sorafenib In Refractory Or Relapsed T-Cell Lymphoma Patients. Blood 2013, 122: 4356. DOI: 10.1182/blood.v122.21.4356.4356.Peer-Reviewed Original ResearchPeripheral T-cell lymphomaCutaneous T-cell lymphomaT-cell lymphomaRefractory T-cell lymphomaStarting doseStage IIBSkin toxicityPilot studyClinical activityRelapsed T-cell lymphomaAllogeneic stem cell transplantAngioimmunoblastic T-cell lymphomaT-cell lymphoma patientsPlatelet-derived growth factor receptor alphaProgression-free survivalStem cell transplantDuration of responseGrowth factor receptor alphaOff-label useT-cell NHLNumber of therapiesMulti-kinase inhibitorAdvisory CommitteeClinical CRStable diseaseUsing Skin Dose Parameters Predicts Low Skin Toxicity in a Phase 2 Trial of Multiple Dwell Position Balloon-Based Brachytherapy for Partial Breast Irradiation
Nath S, Chen Z, Rowe B, Blitzblau R, Aneja S, Grube B, Horowitz N, Weidhaas J. Using Skin Dose Parameters Predicts Low Skin Toxicity in a Phase 2 Trial of Multiple Dwell Position Balloon-Based Brachytherapy for Partial Breast Irradiation. International Journal Of Radiation Oncology • Biology • Physics 2013, 87: s213. DOI: 10.1016/j.ijrobp.2013.06.551.Peer-Reviewed Original ResearchDocetaxel-induced skin toxicities in breast cancer patients subsequent to paclitaxel shortage: a case series and literature review
Poi M, Berger M, Lustberg M, Layman R, Shapiro C, Ramaswamy B, Mrozek E, Olson E, Wesolowski R. Docetaxel-induced skin toxicities in breast cancer patients subsequent to paclitaxel shortage: a case series and literature review. Supportive Care In Cancer 2013, 21: 2679-2686. PMID: 23686402, PMCID: PMC3769512, DOI: 10.1007/s00520-013-1842-3.Peer-Reviewed Original ResearchConceptsBreast cancer patientsSkin toxicityCancer patientsCase seriesGranulocyte colony-stimulating factor supportToxicity eventsColony-stimulating factor supportDose-dense doxorubicinOperable stage IResultsThirty-four patientsSevere skin toxicityEvidence-based preventionElectronic medical recordsInstitutional review boardDermatologic toxicitiesDocetaxel 75Docetaxel monotherapyWeekly paclitaxelCyclophosphamide regimenClinical courseFactor supportMedical recordsTreatment strategiesGrade 3Inclusion criteria
2010
Reduced Skin Toxicity with Multiple Dwell Position Mammosite Brachytherapy: Preliminary Phase II Trial Results
Rowe B, Blitzblau R, Chen Z, Grube B, Weidhaas J. Reduced Skin Toxicity with Multiple Dwell Position Mammosite Brachytherapy: Preliminary Phase II Trial Results. International Journal Of Radiation Oncology • Biology • Physics 2010, 78: s246. DOI: 10.1016/j.ijrobp.2010.07.588.Peer-Reviewed Original Research
2008
Multidwell Position MammoSite Brachytherapy Decreases Skin Toxicity, Preliminary Results of a Phase II Trial
Blitzblau R, Chen Z, Grube B, Weidhaas J. Multidwell Position MammoSite Brachytherapy Decreases Skin Toxicity, Preliminary Results of a Phase II Trial. International Journal Of Radiation Oncology • Biology • Physics 2008, 72: s186. DOI: 10.1016/j.ijrobp.2008.06.757.Peer-Reviewed Original Research
2005
Iron in Skin of Mice with Three Etiologies of Systemic Iron Overload
Adams BD, Lazova R, Andrews NC, Milstone LM. Iron in Skin of Mice with Three Etiologies of Systemic Iron Overload. Journal Of Investigative Dermatology 2005, 125: 1200-1205. PMID: 16354190, PMCID: PMC2243217, DOI: 10.1111/j.0022-202x.2005.23949.x.Peer-Reviewed Original ResearchConceptsSystemic iron overloadHigh-iron dietSkin ironIron overloadIron dietIron levelsSkin of miceTissue iron levelsCutaneous manifestationsSkin of individualsSkin toxicityHistological abnormalitiesHistological changesMouse modelParenteral injectionParenteral administrationHereditary hemochromatosisTissue toxicityHuman hemochromatosisMiceSkin histologyHemochromatosis geneHemochromatosisHigh dietDermis
2003
Targeting the epidermal growth factor receptor: prognostic and clinical implications
Herbst R. Targeting the epidermal growth factor receptor: prognostic and clinical implications. European Journal Of Cancer Supplements 2003, 1: 9-15. DOI: 10.1016/s1359-6349(03)80015-0.Peer-Reviewed Original ResearchEpidermal growth factor receptorGrowth factor receptorEGFR tyrosine kinase inhibitor gefitinibFactor receptorTyrosine kinase inhibitor gefitinibCell lung cancerKinase inhibitor gefitinibPerformance statusClinical responseSkin toxicityPrognostic valueDisease characteristicsLung cancerSurrogate markerClinical trialsNovel anticancer agentsInhibitor gefitinibClinical implicationsGefitinibAntitumour activityBiological markersPromising targetExpression levelsTumorigenic processAnticancer agents
1972
Clinical study with bleomycin: Tolerance to twice weekly dosage
Ohnuma T, Selawry O, Holland J, DeVita V, Shedd D, Hansen H, Muggia F. Clinical study with bleomycin: Tolerance to twice weekly dosage. Cancer 1972, 30: 914-922. PMID: 4116909, DOI: 10.1002/1097-0142(197210)30:4<914::aid-cncr2820300409>3.0.co;2-8.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaCell carcinomaDose levelsObjective tumor responseBody surface areaTherapeutic dose levelsOptimal dose levelNew antineoplastic agentsPulmonary infiltratesTransient hypertensionUrinary burningAbdominal distentionComplete remissionHematologic toxicityCutaneous toxicityWeekly dosesProlonged courseAdditional patientsPatient toleranceSkin toxicityMalignant neoplasmsTesticular carcinomaTumor responseTumor regressionWeekly dosage
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply